At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 603 enrolled
Drug / intervention
APD356-lorcaserin hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation
In Brief
A Phase 2 clinical trial evaluating APD356-lorcaserin hydrochloride and Placebo for Smoking Cessation. Completed, enrolled 603 participants across 31 sites.
Detailed Summary
In smokers who are motivated to stop smoking, treatment with lorcaserin compared with placebo will provide greater abstinence as measured by the last 4 weeks of treatment (Weeks 9-12). The target quit date was Day 15.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartMar 2014
Primary CompletionNov 2014
TodayJul 2026
First PostedJan 24, 2014
Enrollment StartMar 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.4 years ago
Interventions
APD356-lorcaserin hydrochloridedrug
Placebodrug